US2003153626A1PendingUtilityA1

Methods for reducing intraocular pressure

52
Priority: Jul 16, 1998Filed: Feb 25, 2003Published: Aug 14, 2003
Est. expiryJul 16, 2018(expired)· nominal 20-yr term from priority
Inventors:Mortimer M. CivanRichard A. StoneClaire MitchellKenneth A. Jacobson
A61K 31/455A61K 31/4425A61K 31/00A61K 31/138A61P 27/06A61K 31/498A61K 31/517A61K 31/4422A61K 31/435A61K 31/5415
52
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method for decreasing intraocular pressure by administering an A 3 subtype adenosine receptor antagonist, a calmodulin antagonist or an antiestrogen such as tamoxifen. These agents, by inhibiting influx or promoting efflux of aqueous humor, can be used to treat glaucoma.

Claims

exact text as granted — not AI-modified
1 . A method for reducing intraocular pressure in an individual with an ocular disorder, comprising the step of administering to said individual an effective intraocular pressure-reducing amount of a pharmaceutical composition comprising an A 3  subtype adenosine receptor antagonist.  
     
     
         2 . The method of  claim 1 , wherein said A 3  subtype receptor antagonist is a dihydropyridine, pyridine, pyridinium salt or triazoloquinazoline.  
     
     
         3 . The method of  claim 1 , wherein said A 3  subtype receptor antagonist is selected from the group consisting of MRS-1097, MRS-1191, MRS-1220, MRS-1523 and MRS-1649.  
     
     
         4 . The method of  claim 1 , wherein said pharmaceutical composition is administered topically, systemically or orally.  
     
     
         5 . The method of  claim 1 , wherein said pharmaceutical composition is an ointment, gel or eye drops.  
     
     
         6 . The method of  claim 1 , wherein said ocular disorder is glaucoma.  
     
     
         7 . A method for reducing intraocular pressure in an individual with an ocular disorder, comprising the step of administering to said individual an effective intraocular pressure-reducing amount of a pharmaceutical composition comprising an antiestrogen.  
     
     
         8 . The method of  claim 7 , wherein said antiestrogen is tamoxifen.  
     
     
         9 . The method of  claim 7 , wherein said pharmaceutical composition is administered topically, systemically or orally.  
     
     
         10 . The method of  claim 7 , wherein said pharmaceutical composition is ointment, gel or eye drops.  
     
     
         11 . The method of  claim 7 , wherein said ocular disorder is glaucoma.  
     
     
         12 . A method for reducing intraocular pressure in an individual with an ocular disorder, comprising the step of administering to said individual an effective intraocular pressure-reducing amount of a pharmaceutical composition comprising a calmodulin antagonist.  
     
     
         13 . The method of  claim 12 , wherein said calmodulin antagonist is trifluoperazine.  
     
     
         14 . The method of  claim 12 , wherein said pharmaceutical composition is administered topically, systemically or orally.  
     
     
         15 . The method of  claim 12 , wherein said pharmaceutical composition is ointment, gel or eye drops.  
     
     
         16 . The method of  claim 12 , wherein said ocular disorder is glaucoma.  
     
     
         17 . A method for reducing intraocular pressure in an individual with an ocular disorder, comprising the step of administering to said individual an effective intraocular pressure-reducing amount of a pharmaceutical composition comprising a prodrug which is converted into a A 3  subtype adenosine receptor antagonist after said administering step.  
     
     
         18 . An A 3  subtype adenosine receptor antagonist for use in reduction of intraocular pressure.  
     
     
         19 . The A 3  subtype adenosine receptor antagonist of  claim 18 , wherein said receptor antagonist is selected from the group consisting of MRS-1097, MRS-1191, MRS-1523 and MRS-1649.  
     
     
         20 . Use of an antiestrogen in the preparation of a medicament for the reduction of intraocular pressure.  
     
     
         21 . The use of  claim 20 , wherein said antiestrogen is tamoxifen.  
     
     
         22 . A calmodulin antagonist for use in reduction of intraocular pressure.  
     
     
         23 . The calmodulin antagonist of  claim 22 , wherein said calmodulin antagonist is trifluoperazine.  
     
     
         24 . A prodrug which is converted into an A 3  receptor antagonist in vivo for use in reduction of intraocular pressure.

Join the waitlist — get patent alerts

Track US2003153626A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.